Fifer Simon, Toh Lili, Yu Daniel, Young Katherine, Menche Jason
Research, Community and Patient Preference Research (CaPPRe), Sydney, New South Wales, Australia.
Medical, CSL Seqirus, Melbourne, Victoria, Australia.
Hum Vaccin Immunother. 2025 Dec;21(1):2440164. doi: 10.1080/21645515.2024.2440164. Epub 2024 Dec 21.
People in Australia have access to different influenza vaccines, but may be unaware of their options and features. Preference studies for differentiated influenza vaccines including cell-based vaccines are limited, particularly in Australia. This study investigated which influenza vaccine attributes people in Australia value using a discrete choice experiment (DCE). Adults in Australia ineligible for free influenza vaccines had been vaccinated in the last 5 years and intended to be vaccinated again completed an online survey. Participants ( = 1203) were presented three influenza vaccine profiles described by eight attributes. Half the DCE scenarios described influenza season severity to be the same as last year, and the other half as more severe. DCE data were analyzed using a mixed multinomial logit (MMNL) model. All eight attributes significantly predicted vaccine choice ( < .05). Regardless of influenza season severity, participants preferred a vaccine: with greater protection, designed to be an exact match to circulating strains (match), using modern technology, manufactured by an Australian company, available at pharmacies, preferred by health care professionals (HCP), government funded for high-risk individuals and having lower cost. The top three attributes by importance were protection, match and cost. Participants were willing to pay more for match and higher protection. The Marginal Willingness to Pay (MWTP) for the most important attributes, excluding cost, were AUD $1.61/$2.18 for each additional percent in protection (same/more severe season), AUD $25.37/$32.37 for match and AUD $4.06/$15.97 for HCP preference. Findings indicate that match, protection, cost and HCP preference are key to vaccine choice, highlighting the importance of shared decision-making.
澳大利亚人可以接种不同的流感疫苗，但可能并不了解自己的选择及特点。针对包括细胞培养流感疫苗在内的不同流感疫苗的偏好研究有限，在澳大利亚尤其如此。本研究采用离散选择实验（DCE）调查了澳大利亚人重视哪些流感疫苗属性。在过去5年中接种过流感疫苗且打算再次接种的澳大利亚成年人（不符合免费接种流感疫苗条件）完成了一项在线调查。参与者（n = 1203）看到三种由八个属性描述的流感疫苗简介。DCE情景的一半描述流感季节严重程度与去年相同，另一半描述为更严重。使用混合多项logit（MMNL）模型分析DCE数据。所有八个属性均显著预测了疫苗选择（P <.05）。无论流感季节严重程度如何，参与者都更喜欢一种疫苗：具有更高的保护效果、设计为与流行毒株完全匹配（匹配度）、采用现代技术、由澳大利亚公司生产、可在药店购买、受医护人员（HCP）青睐、政府为高危人群提供资金支持且成本较低。重要性排名前三的属性是保护效果、匹配度和成本。参与者愿意为匹配度和更高的保护效果支付更多费用。除成本外，最重要属性的边际支付意愿（MWTP）为：在保护效果方面，每增加一个百分点（相同/更严重季节）分别为1.61澳元/2.18澳元；匹配度为25.37澳元/32.37澳元；HCP偏好为4.06澳元/15.97澳元。研究结果表明，匹配度、保护效果、成本和HCP偏好是疫苗选择的关键，凸显了共同决策的重要性。
